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Abstract 
Wnt signaling is overactivated in triple-negative breast cancer (TNBC) and several other cancers, and 
its suppression emerges as an effective anticancer treatment. However, no drugs targeting the Wnt 
pathway exist on the market nor in advanced clinical trials. Here we provide a comprehensive body of 
preclinical evidence that an anti-leprotic drug clofazimine is effective against TNBC. Clofazimine 
specifically inhibits canonical Wnt signaling in a panel of TNBC cells in vitro. In several mouse 
xenograft models of TNBC, clofazimine efficiently suppresses tumor growth, correlating with in vivo 
inhibition of the Wnt pathway in the tumors. Clofazimine is well compatible with doxorubicin, exerting 
additive effects on tumor growth suppression, producing no adverse effects. Its excellent and well-
characterized pharmacokinetics profile, lack of serious adverse effects at moderate (yet therapeutically 
effective) doses, its combinability with cytotoxic therapeutics, and the novel mechanistic mode of 
action make clofazimine a prime candidate for the repositioning clinical trials. Our work may bring 
forward the anti-Wnt targeted therapy, desperately needed for thousands of patients currently lacking 
targeted treatments. 
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1. Introduction1 
Wnt signaling is a highly evolutionary conserved developmental signal transduction pathway, which 
controls multiple events during embryogenesis regulating cell proliferation, differentiation, motility, 
migration and polarization [1]. No wonder that the Wnt pathway, as it is the case for many other 
developmental pathways, is frequently hijacked by cancer cells that employ most of the above-
mentioned features for promotion of tumor growth, metastasis and drug resistance. Targeting of the 
Wnt pathway is therefore an attractive option for development of new anticancer drugs [2, 3]. 
However, many of the anti-Wnt compounds failed to show an acceptable safety profile, mainly due to 
the function of the adult Wnt pathway in controlling tissue renewal and regeneration in the adult organs 
[4]. Therefore, the search for efficient and safe compounds targeting the Wnt pathway must go on. 
Clofazimine is a riminophenazine derivative – a fully synthetic product based on a chemical scaffold 
initially obtained from lichens [5]. This drug was discovered in 1950s and approved as an essential part 
of the anti-leprosy complex treatment; however until today there is no consensus on the mechanism of 
its anti-bacterial activity [6, 7]. Reports on identification of clofazimine as an anticancer compound 
first appeared in mid-90s, however few mechanistic studies have been performed [8]. Those few 
identify clofazimine as an inhibitor of mitochondrial Kv1.3 channels [9], as a regulator of the PLA2-
induced cell death [10], or as an agent interfering with enzymes of the respiratory chain [11]. In our 
previous work, we reported identification of clofazimine as a novel inhibitor of Wnt signaling [12]. 
Taken together, these prior data point towards several mechanisms, which clofazimine might employ 
for suppression of cancer cell growth and induction of cell death. 
Despite this multi-faceted activity profile, clofazimine is an agent with surprisingly few adverse effects: 
upon normal dosage it induces only grade 1-2 toxicities, and reaches higher grades only upon overdose 
[13]. This low toxicity profile creates significant hope for the repositioning of clofazimine as a targeted 
                                                 
Abbreviations: TNBC – triple-negative breast cancer; PLA2 – phospholipase A2; NSG – NOD-SCID-gamma; CDI – 
coefficient of drug interaction 
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therapy against numerous Wnt-dependent cancer types. It should be noted that the drug has already 
quite a track record of repositioning. Upon discovery, it was not approved for the treatment of 
tuberculosis, for which it had initially been developed, mostly due to lower efficacy and cosmetic 
defects upon application, and is currently approved only as a second-line therapy against the multidrug 
resistant tuberculosis [14]. Since leprosy is caused by another species of the Mycobacterium family, the 
drug was retested and further marketed as an agent against this disease [15]. In the beginning of 90’s, 
anti-inflammatory properties of the compound were identified and, given its anti-microbial effect, the 
scope of applications of clofazimine was broadened to the treatment of skin infections caused by 
microorganisms [16]. Currently, clofazimine experiences a comeback as an anti-tuberculosis agent due 
to the rise of multidrug-resistant strains of this disease, which are still susceptible to clofazimine [17]. 
Much effort has been put in the compound development using modern medicinal chemistry approaches 
in order to reduce or completely eliminate its main side-effect – the skin discoloration [18-20]. 
The current work continues the exploration of the anti-Wnt properties of clofazimine and evaluates the 
preclinical anticancer efficacy and safety profiles of the drug in vitro and in vivo on a panel of TNBC 
(triple-negative breast cancer) cell lines and two xenograft models. Our results confirm that in TNBC, 
clofazimine acts through inhibition of Wnt signaling and that this activity mediates its growth-
inhibitory effects against a broad scope of TNBC tumors. Finally, we have investigated the interaction 
profile of clofazimine with a conventional cytotoxic agent doxorubicin in vitro and in vivo. Overall, 
these data pave the way for the clinical trials of clofazimine as a safe and efficient Wnt-targeting anti-
cancer agent. 
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2. Materials and methods 
2.1. Luciferase activity measurements  
The Wnt-induced and basal luciferase activity was analyzed as described [12, 21]. Briefly, 100μl of BT-
20 cells, wild type or stably transfected with the TopFlash luciferase reporter [12] at 150000 cells/ml 
were distributed in a white opaque 96-well or 384-well plate. The cells were maintained in DMEM 
containing 10% FBS and incubated at 37°C, 5% CO2 overnight for attachment. Afterwards, the stably 
transfected BT-20 cells were additionally transfected with the plasmid constitutively (under the CMV 
promoter) expressing Renilla luciferase (Addgene, Cambridge, MA, USA), whereas wild-type cells 
were transfected by the 5:5:2 mixture of a reporter plasmid (Syngene), a Wnt5a-encoding or control 
plasmid and the Renilla luciferase plasmid. Transfection was carried out as described in the 
manufacturer’s protocol using 12µg/ml of DNA and 40µl/ml XtremeGENE 9 reagent (Roche). 
The next day, the medium of each well was replaced by 50μl (96-well plates) or 30μl (384-well plates) 
fresh medium containing Wnt3a (500ng/ml) (purified as described [22]) and clofazimine at 
concentrations indicated in the figures (following 1h of pre-incubation with the compound). After 
overnight incubation, the supernatant in each well was removed and the luciferase activity was 
measured as described [12]. After 24h incubation, the cells were harvested and analyzed for activities 
of both firefly and Renilla luciferase as described [12, 21]. 
2.2. Western blot for Wnt target genes 
Different TNBC and non-TNBC cell lines as indicated in the figures were seeded at 700’000 cells/well 
in 6-well plates. The next day, the medium was removed and replaced with a fresh medium pre-warmed 
to 37°C with or without clofazimine at 20µM. After 1h pre-incubation, if indicated, Wnt3a was added at 
200ng/ml. After 24h incubation at 37°C, the medium was removed, the cells in each well were washed 
twice with 500µl of 1x PBS and lysed directly in the well by addition of 100µl of ice-cold RIPA buffer 
(1x TBS, 4mM EDTA, 1% Triton, 0.1% SDS, 1x Protease inhibitor cocktail (Roche)) for 10min. The 
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cells were re-suspended and the debris was removed by 10min centrifugation at 16000g, 4°C. The 
supernatants were further analyzed by Western blot with antibodies against c-Myc (Abcam), Axin2 
(Abcam) and α-tubulin (Sigma) at 1:1000 dilution each. 
2.3. MTT assay  
100μl of the indicated TNBC cell lines re-suspended at 30’000 cells/ml (100’000/ml for HCC-38 or 
250’000/ml for IOWA-1T) were added into each well of a transparent 96-well plate. The cells were 
maintained in DMEM (DMEM/F12 in case of IOWA-1T) containing 10% FBS and incubated at 37°C, 
5% CO2 overnight. The medium of each well was replaced by 100μl fresh medium the next day 
containing the indicated concentrations of clofazimine. In case of combination experiments, the cells 
were first covered with 50µl of medium, and desired concentrations of clofazimine and doxorubicin in 
the well were created by adding them in 25µl of the corresponding pre-dilutions in the DMEM. After 
incubation for 3-4 days, the medium in each well was replaced by 100μl of 0.5 mg/ml Thiazolyl blue 
(Carl Roth) solution in 1xPBS. In case of IOWA-1T, which is a suspension cell line, 75μl of 1.5mg/ml 
Thiazolyl blue solution was added directly in the 150μl of the medium. The plates were incubated for 
3h at 37°C. Then the solution was removed and 50μl DMSO was added into each well. In case of 
IOWA-1T, the plates were centrifuged at 1000g for 1min and the supernatant was carefully removed 
prior to addition of DMSO. Absorbance at 570nm was measured in a plate reader (Victor3, 
PerkinElmer). 
2.4. Apoptosis and cell cycle assays 
Indicated cell lines were seeded at 500’000 per well in 6-well plates and incubated for 24h in presence 
of 20µM clofazimine or DMSO. The cells were detached using the Accutase solution (BD) and stained 
for the corresponding assays. Apoptosis levels were measured using the Annexin V/PI staining kit 
(Sigma-Aldrich) according to the manufacturer’s instructions. For cell cycle analysis, the cells were 
fixed in 70% EtOH and stained with propidium iodide prior to analysis. For both assays, measurements 
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were performed with the BD Galleos flow cytometer and the results were analyzed using the Flowing 
Software 2.5 (Turku University). 
2.5. Scratch-wound and colony formation assays with TNBC cells 
For migration analysis, the scratch-wound assay was used. Cells were seeded at 60’000 cells/well in 
96-well flat-bottom plates. Next day, after attachment, the monolayer formed in each well was 
wounded in two places by a single strike of a 10µl pipette tip. The detached cells were removed by two 
washes with 1xPBS. For each experimental well, a random area of both scratches was labeled and a 
phase-contrast picture was taken. The cells were left for 24h in presence or absence of 20µM 
clofazimine. Afterwards, pictures of the same area were taken and the migration of the cell front was 
analyzed by ImageJ. 
For the colony formation assay, TNBC cells were seeded at 250 cells/well for HCC-1395, MDA-MB-
231 and HCC-38; 500/well for MBA-MB-468; 750/well for BT-20 and 1000/well for HCC-1806 in 6-
well plates. Next day, the medium was replaced with the one containing 20µM clofazimine. Colonies 
of 70-100 cells were formed after 8-14 days, were fixed by incubation in 4% PFA in 1xPBS, pH 7.4 
and visualized by staining with the crystal violet solution, and the number of colonies was counted. 
2.6. Mouse xenografts 
The experiments were approved by the Swiss Federal Veterinary Office and were carried out in 
accordance with the local animal welfare act. NOD-SCID-gamma (NSG) mice were injected 
intramammary with 50µl suspension of the following cells: 2×106 BT-20 cells stably transfected with 
pcDNA3-Luciferase construct (Addgene, Cambridge, MA, USA) or 5×105 IOWA-1T cells. For 
injection, the cells were detached by trypsin, washed 2x with ice-cold PBS and re-suspended in ice-
cold Matrigel (BD, Franklin Lakes, NJ, USA, cat. #356237). Tumor volume (mm3) was determined 
using the following formula: tumor volume = length×(width)2×π/6. The drug treatment was started as 
soon as the tumor reached the volume of ~100mm3. 
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For clofazimine treatment, the mice were separated into two groups: one receiving the drug and another 
receiving the vehicle (N=5 each in case of IOWA-1T; N=3 for vehicle, N=4 for drug treatment in case 
of BT-20). Clofazimine (2.5-10mg/ml, depending on the dose) was delivered by oral gavage as 
suspension in 10% Kolliphor, 1% CMC. The drug treatment group in all cases received the 200mg/kg 
“loading dose” of clofazimine for 3 days in a row prior to switching to the doses delivered once in two 
days, as indicated in the figures and text. For the combination treatment, mice were separated into four 
groups: vehicle-treated (N=5), doxorubicin-treated (N=3), clofazimine-treated (N=4) and combination-
treated (N=4). These animals were treated by clofazimine or vehicle as described above and 
additionally the appropriate groups received 2mg/kg once in 3 weeks injections of doxorubicin 
dissolved in 1xPBS at 0.5mg/ml. 
In vivo imaging was performed using IVIS Lumina II (Xenogen). Mice were injected with 50mg/kg D-
luciferin solution (Goldbio St. Louis, MO, USA) and luminescence was measured 10min post-
injection. Intensity (expressed as photon flow) was quantified using the Living Image (PerkinElmer, 
Waltham, USA) software. 
The coefficient of drug interaction (CDI) was calculated according to the following equation [23]: 
CDI=R12/(R1×R2)  where R12 is a tumor size in the combination-treated animals, and R1 and R2 are 
tumor sizes of the animals treated by each of the compounds alone. 
2.7. Slide preparation and immunofluorescent staining 
After removal from the animals, tumors were photographed, sliced into fragments of ~300-400mm3 
and rinsed in the excess of ice-cold 1xPBS. Subsequently, they were fixed in fresh 10% PFA solution in 
1xPBS for 3-5 days at 4oC. The tumors were embedded in paraffin blocks and cut into slices 7-10µm 
thick. The slices were mounted on glass slides and stored at 4oC. For the staining, the slides were first 
deparaffinized in three changes each of xylene, sequence of water mixtures of EtOH with decreasing 
concentrations (95%, 70% and 50%) and finally water. Subsequently, antigen retrieval was performed 
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in 20mM Tris-EDTA, pH 9.0 with 0.1% Tween-20 by heating up the slides to 95oC for 20min and 
gradual cooling to the room temperature. Further, the slides were blocked in 1xPBS/0.1% Triton X-100 
with 3% of normal horse serum and stained with primary antibodies against β-catenin (BD 
Biosciences), MDR-1 (Sigma), Ki67 (BD Biosciences) at 1:200 dilution. Cleaved caspase-3 staining 
was performed using the respective antibodies (CST) at the 1:1’000 dilution and developed using the 
SuperBoost tyramide enhancer kit (Invitrogen). The slides were mounted using VectaSchield mounting 
medium and visualized using AiryScan LSM-880 confocal microscope (Zeiss). For scoring, each of the 
stained slides was assigned with the perceived level of membrane or cytoplasmic staining ranging from 
0 (not observed) to 5 (maximum); the average score for all the stained tumors was calculated for 
presentation. 
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3. Results 
3.1. Clofazimine is an efficient and specific inhibitor of the canonical Wnt signaling in a broad 
range of TNBC subtypes 
In our previous work [12], we demonstrated that clofazimine efficiently inhibited exogenous Wnt3a-
induced signaling in HEK293T cells. Proliferation of the triple-negative breast cancer (TNBC) cell line 
BT-20, known to be dependent on the endogenous Wnt pathway activation [24], was inhibited with the 
similar IC50 of ca. 6µM [12]. Here, we first directly show that Wnt3a-induced signaling in BT-20 cells 
is inhibited with increasing concentrations of clofazimine, with the IC50 = 7µM, as measured with the 
TopFlash assay (Figure 1A). Noteworthy, acute cell toxicity measured by co-transfection with the Wnt-
independent transcriptional Renilla reporter could only be observed with clofazimine concentrations 
approaching 100µM (Figure 1B). As an additional readout of Wnt signaling in BT-20 cells, we 
monitored expression of Axin2 and c-Myc as two well-established [25-28] readouts of the Wnt 
signaling activity. Both endogenous and ectopic Wnt3a-induced levels of Axin2 and c-Myc were 
significantly suppressed by 20M clofazimine (Figure 1C). 
As TNBC is a heterogeneous disease, we next addressed whether the drug can reliably suppress Wnt 
signaling in a panel of TNBC cell lines. Additionally, non-TNBC breast cancer (BC) cell lines were 
also included in the analysis, since the Wnt pathway can be dysregulated also in other BC subtypes 
[26]. The panel we analyzed represented the clinical diversity of TNBC: three cell lines were luminal-
like ductal (BT-20), squamous (HCC-1806) and adeno-carcinoma (MDA-MB-468); one was basal-like 
adeno-carcinoma (MDA-MB-231); IOWA-1T represents TNBC stem cells population [29]; finally, 
HER2+ and ER/PR+ BCs were represented by MCF-7 and MDA-MB-453 cell lines, respectively. 
Clofazimine suppressed Axin2 in all the analyzed cell lines (Figure 1C-I). c-Myc was suppressed by 
clofazimine in most cell lines; however, in three of them (TNBC cell lines MDA-MB-468 and HCC-
1806, and ER/PR+ MDA-MB-453 cells) the levels of this protein remained intact (Figure 1E, G, I). 
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We also ectopically stimulated the BC cell lines by purified Wnt3a. In response, Wnt target genes were 
found to be upregulated in most BC lines (Figure 1C-F). For these lines, we additionally verified the 
ability of clofazimine to suppress this induced response. For all these lines including MDA-MB-468 
(where basal c-Myc levels were insensitive to the drug), clofazimine was able to decrease the response 
to purified Wnt3a (Figure 1C-F). 
While the above readouts monitor the Wnt pathway at the level of target gene transcription, 
cytoplasmic and nuclear β-catenin represents a readout for more upstream levels of the pathway. TNBC 
cells have high endogenous levels of cytonuclear β-catenin through continuous activation of the Wnt 
pathway [30, 31]. We thus analyzed the long-term effects of clofazimine on β-catenin levels in BT-20 
cells, finding that 48h drug treatment markedly decreased cytoplasmic β-catenin (from ca. 15% control 
cells positive for strong cytoplasmic β-catenin to ca. 2% upon clofazimine treatment) (Fig. 1J). In 
contrast, the membranic pool of β-catenin (mediating cell-cell contacts and not involved in the Wnt 
pathway [32]) remained relatively unaffected.  
Taken together, these results indicate that clofazimine suppresses the canonical Wnt pathway 
(endogenous and exogenously induced), as measured by expression of Axin2, c-Myc, and TopFlash 
reporter genes/constructs in a broad panel of BC cell lines, as well as by monitoring cytoplasmic β-
catenin levels. It appears that c-Myc expression in some cell lines is largely influenced by mechanisms 
additional to Wnt signaling [26]. 
We also accessed the specificity of clofazimine-induced inhibition of the canonical Wnt pathway using 
a set of luciferase reporters for other pathways (Supplementary Fig. 1). We found that in BT-20 cells, 
C/EBP and NFκB pathways were stimulated by Wnt5a – a non-canonical Wnt ligand [33] 
(Supplementary Fig. 1A and B), indicating that they may serve as the readouts of non-canonical Wnt 
pathway activity. Interaction between non-canonical Wnt pathway and MAPK pathway (one of which 
readouts is C/EBP) is well established [34, 35] and direct interaction of Wnt pathway with this 
transcriptional factor is crucial for adipocyte development [36, 37]. Both MAPK and NFκB pathways 
12 
 
are promoted in non-canonical Wnt5a-dependent manner in dental pulp cells [38], while overall 
crosstalk between Wnt and NFκB is well described in various inflammatory models [39, 40]. However, 
clofazimine was unable to suppress activity of these pathways, both basal and Wnt5a-stimulated. 
Equally, clofazimine treatment exerted no effect in the panel of nine other pathway reporters 
(Supplementary Fig. 1C) indicating high specificity of the clofazimine inhibition towards canonical 
Wnt pathway. 
 
3.2. Clofazimine suppresses growth of a panel of TNBC cell lines through induction of apoptosis 
and cell cycle arrest 
We next moved to profile the anticancer properties of clofazimine against six TNBC cell lines (the cells 
used in Figure 1 above plus two additional basal-like ductal carcinoma cells, HCC-1395 and HCC-38) 
analyzing the drug’s ability to suppress cell proliferation using the MTT assay. Concentration-
dependent curves (Figure 2A, B) identified that IC50 of clofazimine against the TNBC lines lied within 
the 3-8µM interval agreeing well with its anti-Wnt IC50 (Figure 1A) and with the IC50 of growth 
suppression of BT-20 (6µM) we had reported earlier [12]. This proliferation arrest correlated well with 
the ability of clofazimine to suppress clonogenicity of a panel of TNBC cell lines (Figure 2C, D). 
To analyze the mechanism of BC growth inhibition induced by clofazimine, we applied the Annexin V 
staining to assess the percentage of apoptotic and necrotic cells (Figure 2E), and propidium iodide 
staining to assess the cell cycle progression of the cells after clofazimine treatment (Figure 2F). The 
results indicate that clofazimine exerts a mixed mode of action to suppress proliferation of different BC 
lines, combining the induction of apoptosis with the G2/M-phase arrest.  
In contrast to the clear anti-proliferative activity of the drug, clofazimine revealed only a limited effect 
on cancer cell motility as measured in the wound healing assay, partially suppressing motility of MDA-
MB-231 and MDA-MB-468 but no other TNBC cell lines at 10µM (Figure 2G, H). This finding was 
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expected, as tumor cell migration is known to depend less on the canonical Wnt pathway than other 
tumor characteristics [41]. 
3.3. TNBC tumor xenograft growth is suppressed by oral clofazimine 
We continued our investigation by testing how oral regimen of clofazimine would affect growth of 
human TNBC cells grafted intramammary in NOD-SCID-gamma (NSG) mouse hosts. The drug is 
highly bioavailable and its allometric and pharmacokinetic properties are well described [42]. We 
therefore selected 50 and 100 mg/kg doses administered every other day since they corresponded to the 
maximal tested doses of clofazimine in humans (100-300 mg/day, [42, 43]). In agreement with the in 
vitro results described above, clofazimine delivery by oral gavage resulted in a profound suppression of 
the tumor growth initiated by IOWA-1T (Figure 3A-D) and BT-20 cells (Figure 3E-H) as estimated by 
electronic calipers during the trial run (Figure 3A, F) as well as tumor volume estimation after the 
animals’ sacrifice (Figure 3C, D). Luminescence measurements from the tumors (BT-20 cells were 
stably transfected with constitutive firefly luciferase prior to xenografting) provided an additional 
readout (Figure 3E, H) confirming the manual assessment of the tumor volumes. Importantly, no 
adverse effects of 50 or 100 mg/kg clofazimine treatment were observed, as illustrated by the lack of 
body weight loss (Figure 3B, G) nor any other parameters (see below, Supplementary Tables 1 and 2). 
Moreover, our re-run of the trial with a decreased dose of clofazimine (25mg/kg) yielded similar 
decrease of the tumor volume as was observed for 50 and 100 mg/kg dosage (Supplementary Fig. 2). 
 
3.4. On-target effect of clofazimine in vivo 
We further investigated whether the growth suppression of the xenografted tumor cells correlated with 
the inhibition of Wnt signaling in the tumor. To this end, we performed immunohistochemistry analysis 
of fixed paraffin slides of the tumors against two well established markers of Wnt signaling – β-catenin 
and its target gene MDR-1 [25, 26, 31, 44].  
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β-catenin revealed a striking change of the pattern of its intracellular distribution upon clofazimine 
treatment (Figure 4A). In control tumors, the vast majority of the cells displayed a strong cytoplasmic 
pattern correlating well with the high levels of activity of Wnt signaling in these cells in the growing 
tumor [31, 45]. Upon clofazimine treatment, a dramatic increase was seen in the number of cells losing 
cytoplasmic β-catenin and exclusively showing the membrane β-catenin staining pattern, typical for 
low Wnt signaling levels, with the plasma membrane pool of β-catenin mediating Wnt-independent 
cell-cell contact function [45] (Figure 4A). To account for the heterogeneity of IOWA-1T xenograft 
tumors, we quantified the slides for the relative number of cells divided into four subtypes by the 
observed level of membrane and cytoplasmic β-catenin (Figure 4B) as well as performed slide scoring 
(Figure 4C) followed by statistical analysis. All these analyses clearly confirm the qualitative 
observations and reveal a picture of dramatic clofazimine-induced switch from the Wnt-on to the Wnt-
off status of the tumor cells. These in vivo findings correlate with the decrease of cytoplasmic β-catenin 
induced by clofazimine in cultured TNBC cells (Figure 1J above).  
The second Wnt signaling marker, MDR-1, is a very attractive Wnt target gene due to its well-known 
function in the development of tumor drug resistance [46-48]. Upon visual inspection of the stainings, 
we observed a significant decrease in MDR-1 levels in the tumors after clofazimine treatment (Figure 
4A). Since MDR-1 staining was not homogenous but appeared as staining-positive “zones”, in order to 
quantify this decrease of MDR-1 staining, we counted these zones in the area of the same size between 
control and clofazimine-treated samples (Figure 4D). Such investigation revealed a clear quantifiable 
reduction in occurrence of such zones, along with their reduced brightness in clofazimine-treated 
samples. 
We also confirmed that decreased growth in clofazimine-treated tumors is related to the pro-apoptotic 
and cell cycle-related effects of the clofazimine as we observed above in the in vitro experiments 
(Figure 2A). Indeed, immunofluorescent staining of the clofazimine-treated and control tumors for 
Ki67 and cleaved caspase-3 revealed that clofazimine-treated tumors have lower proportions of 
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actively dividing cells and dramatically increased (around 5-fold) numbers of the apoptotic cleaved 
caspase-3-positive cells (Figure 4E and F). 
 
3.5. Clofazimine is compatible with the cytotoxic chemotherapy agent doxorubicin and this drug 
combination demonstrates additive effects in vitro and in vivo 
Depending on the exact diagnosis, targeted therapies are often combined with the reduced or even full 
regimens of the conventional cytotoxic agents [49-51]. It is therefore imperative to evaluate the effects 
of a drug interaction for any novel potential targeted agent. We thus further investigated the effects of 
clofazimine in the xenograft-bearing animals in combination with doxorubicin – a well-known 
chemotherapeutic agent and one of the first-line therapies for TNBC [52]. We used it at 2mg/kg once in 
3 weeks combined with clofazimine at 25 mg/kg daily, while the compounds alone, together with 
vehicle treatments, served as controls. The clofazimine+doxorubicin combination clearly and 
significantly exceeded the effects of either drugs when used alone (Figure 5A). Interestingly, while 
doxorubicin resulted in a significant systematic weight loss by the animals, the combination treatment 
did not aggravate this effect. In contrast, the combination rather tended to reduce this adverse effect of 
doxorubicin (Figure 5B). No other adverse reactions for control or treatment groups were identified 
during the study, which monitored parameters such as appearance of urine and feces, appearance of the 
skin, orifices, conscience and posture, see Supplementary Tables 1 and 2). Similarly, no overt organ 
damage was observed upon examination after sacrifice (data not shown). These data speak of an 
excellent in vivo compatibility of clofazimine with doxorubicin – both in terms of additive therapeutic 
effect and lack of aggravated adverse reaction. 
The drug combination effect can be expressed quantitatively using various approaches. For the in vivo 
trial, we estimated the coefficient of drug interaction (CDI, [23], see materials and methods) for each 
day of the trial. This simple coefficient is useful when it is difficult to perform a dose-dependent study 
and shows values from zero to one if the effect of the two compound is synergistic, and above one in 
16 
 
the case of antagonism. As demonstrated on Figure 5C, when calculated for each time point, the CDI 
fluctuated around one starting from the very beginning of the measurements, and averaged at 1.06 over 
the whole period of treatment. This is a clear indicative of additivity of these compounds on the tumor 
growth. 
We decided to investigate this effect in more details in vitro using our panel of TNBC cell lines. We 
employed a comprehensive 2D approach for the drug combination analysis, assessing drug interactions 
over the complete range of effective doses for the two drugs. It was followed by Loewe modeling for 
estimation of the drug combination effect using the Combenefit software [53]. The main readout of this 
analysis is called the synergism/antagonism matrix where for each combination point, the coefficient 
ranges from -100 (the strongest antagonism) to +100 (the strongest synergism) and is coded in the color 
other than light green in case if the value passes statistical significance test (Supplementary Figure 3). 
As can be seen from representative examples of these matrices for different TNBC cell lines 
(Supplementary Figure 3), paralleling the in vivo results, this coefficient fluctuates around zero for 
most of concentration ranges across the TNBC panel, indicating predominance of the additive effect. 
The magnitude of any observed synergistic or antagonistic effects is small and may be found only in a 
narrow concentration range (Supplementary Figure 3 and 4). 
Quantitatively, this is summarized on Figure 5D, where we used the weighted summary synergism and 
antagonism values calculated for such matrix from each independent repeat. It is evident that for all the 
cell lines, areas of weak synergism exist (along with areas of weak antagonism). The overall score of 
the synergistic effect is within the range of 5-15, which means that broadly the interaction between 
clofazimine and doxorubicin can be considered additive rather than synergistic. 
We can therefore summarize that clofazimine and doxorubicin are compatible in vivo and in vitro, and 
that their anticancer effect is overall additive, with concomitant absence of additivity of adverse effects. 
Cumulatively, these findings lay the ground for the clinical development of clofazimine as targeted 
anticancer therapy, to be potentially applied in combination with conventional cytotoxic therapies. 
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3. Discussion 
The ability of clofazimine to inhibit growth of cancer cells in vitro was first discovered and evaluated 
in mid-90s [10, 11, 54, 55]. However, these studies were typically not supported by mechanistic 
investigation, impeding subsequent drug development. Thus, anti-cancer clinical trials of clofazimine 
were small-scale, largely inconclusive and did not have a continuation [54, 56]. Our re-discovery of 
clofazimine as an anticancer agent with a clear mechanism of action within the Wnt pathway [12] 
provided new hope for application of this compound and its derivatives in oncology. Our current work 
directs these prior findings to one of the most troublesome and deadly cancers – triple-negative breast 
cancer (TNBC) – which is known to depend on the activity of the Wnt pathway [26, 57]. We selected a 
panel of TNBC cell lines representing major clinically relevant subtypes (luminal-like, basal-like) as 
well as tumor-initiating cells (“cancer stem cells”), which are responsible for the resistance of this 
disease to chemotherapy [58]. We profiled the activity of clofazimine, both in terms of inhibition of the 
Wnt pathway and inhibition of cell proliferation, against this panel, revealing the strong promise of the 
drug against various TNBC lines including the tumor-initiating cells. 
These data, taken together with the well-established safety profile of clofazimine, prompted us to 
confirm its activity using in vivo models. We chose BT-20 as a somatic cancer cell line with a proven 
track of Wnt-dependent growth [24, 59], and the IOWA-1T line corresponding to the chemoresistant 
cancer progenitor population [29], which has also been described to have and depend on high levels of 
Wnt signaling [60, 61]. The second line was also our obvious choice for combination treatment, since it 
is particularly relevant for chemoresisitant tumors. 
The dosage was adjusted based on the known data on clofazimine dose/plasma levels and tissue 
accumulation, as well as allometric scaling described for the drug [42, 43]. Thus, 50mg/kg of oral 
clofazimine given every other day in mice corresponded to about 100-300 mg per day of the human 
dose and expected to result in around 50-100µM of tissue levels (up to 500µM in some tissues) which 
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is well above its typical in vitro IC50 of 3-8µM. It should be noted that lipophilic clofazimine has an 
extreme propensity to accumulate in tissues, while its blood plasma levels remain flat at around 1µM at 
the doses above around 10mg/kg [42]. Correspondingly, clofazimine demonstrated a profound ability to 
inhibit tumor growth in the two xenograft models we studied, including highly aggressive and fast-
growing tumor derived from the IOWA-1T cell line, which is highly resistant to a conventional anti-
TNBC therapy doxorubicin in vivo (Figure 5A, [29]). In addition to this anti-cancer effect, we observed 
no overt adverse reactions in the animals. The anti-tumor effect, in contrast, was observed even at the 
low doses (25 mg/kg) indicating potentially a very broad therapeutic window for the compound. 
Despite many investigations of clofazimine action on cultured cells, only a few studies dealt with 
molecular understanding of the target and the mode of action of the drug. One of such line of studies 
highlighted the potassium channel Kv1.3 as a target of clofazimine, with inhibition of the channel by 
the drug inducing cancer cell apoptosis through mitochondrial ROS production [9, 62] in preclinical 
models of chronic lymphocytic leukemia [9], melanoma [62] and pancreatic adenocarcinoma [63]. 
Inhibitors of Kv1.3 are known to be immunosuppressive, and such properties of clofazimine have been 
described even prior to the discovery of its ability to inhibit Kv1.3 [7, 16]. Among the immune cells, 
clofazimine preferentially targets T-cells through Kv1.3 and macrophages through formation of 
biocrystals [64, 65]. These inhibitions might produce conflicting effects on the anti-tumor immunity, as 
the tumor-infiltrating lymphocytes exert anti-tumor activities [66], while tumor-associated 
macrophages are generally considered to be immunosuppressive and are associated with poor clinical 
outcome [67]. The respectful role of the molecular target of clofazimine (Kv1.3 vs. the Wnt pathway vs. 
both at once) in different tumor types, as well of the role of clofazimine-mediated inhibition of one or 
both of these targets in different types of tumor-associated immune cells, awaits further investigation. It 
is worth mentioning in this regard that activation the tumor Wnt pathway promotes evasion from the 
immune control through enhanced PD-L1 expression in TNBC [68]. 
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Focusing on Wnt signaling in TNBC, we identified a profound on-target effect of clofazimine in the 
animal models. The drug blocked β-catenin accumulation in the cytoplasm of tumor cells, representing 
a switch from a Wnt-on to the Wnt-off state. Additionally, reduction in a Wnt target gene MDR-1 was 
observed upon clofazimine treatment. Apart from being and additional confirmation of clofazimine on-
target effect in vivo, this finding provides a mechanistic explanation to the phenomenon of MDR-1-
related chemosensitization observed for clofazimine at the dawn of studies of its anti-cancer activity 
[55, 69]. We further report here the investigation of combination of clofazimine with doxorubicin, one 
of the most frequently used treatments for TNBC. The two drugs largely reveal additive anti-tumor 
effects in vitro and in vivo, without additivity for the adverse effects, agreeing with the prior clinical 
trial on combining clofazimine with doxorubicin, which demonstrated no additional toxicity [56]. 
 
Overall, our work paints clofazimine as a highly promising targeted drug against TNBC and other Wnt-
dependent tumors. Decades of application of the drug to patients with infectious diseases have 
established a thorough PK profile with detailed description of the expectable moderate side effects. The 
novel mechanism of action of the drug and its additivity with a conventional chemotherapy permits 
initiation of repositioning clinical trials. In case of success, this work will bring about first targeted 
therapy against the deadliest form of breast cancer.  
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Figure legends 
Figure 1. Wnt signaling is suppressed in various TNBC and non-TNBC cell lines (A,B) Dose-
dependent inhibition of the Wnt3a-induced response in BT-20 TNBC cells transfected with the Wnt-
dependent TopFlash reporter construct (A) and with the Wnt-independent CMV-Renilla reporter 
construct (B). (C-F) Endogenous and Wnt3a-induced expression levels of the Wnt target genes Axin2 
and c-Myc are reduced in a panel of BC cell lines. Representative Western blots are shown on the left 
of each panel, and quantification of expression – on the right. (G-I) In three BC lines, ectopic Wnt3a 
did not increase Axin2 and c-Myc levels, yet the endogenous levels of these target genes were sensitive 
to clofazimine. (J) Immunofluorescent staining of β-catenin in BT-20 cells treated with clofazimine for 
48h reveals a dramatic decrease in the cells positive for cytoplasmic β-catenin (marked with arrows); 
quantification is provided on the right. 
 
Figure 2. Treatement with clofazimine reduces cancer hallmarks and induces apoptosis and cell 
cycle arrest (A,B) Dose-dependent survival curves (A) and IC50 values (B) of clofazimine obtained for 
a panel of six TNBC cell lines. (C,D) Clofazimine (20µM) potently suppresses colony formation by the 
TNBC cell lines; MDA-MB-468 cells are shown as example (D). (E,F) Analysis of apoptosis and cell 
cycle progression in the 20µM clofazimine-treated cell lines demonstrate that the drug uses both these 
mechanisms to exert its effect on tumor cells. Data are provided as percentage to the vehicle-treated 
cells. (G,H) Scratch-wound assay indicates that clofazimine at 20µM has little or no effect on the 
migration ability of TNBC cells. Only two cell lines, MDA-MB-231 and MDA-MB-468, were 
sensitive to the drug; MDA-MB-468 cells are shown as example (H). 
 
Figure 3. TNBC xenograft tumor growth is suppressed by oral clofazimine (A-D) Treatment of 
intramammary IOWA-1T tumor xenograft-bearing NGS mice results in significant suppression of 
tumor growth at both 100 and 50 mg/kg daily oral dose. On (A) the graph shows tumor volume 
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estimated by electronic calipers. Body weight (B) remains stable across the experiment. (C) shows the 
tumors extracted from the animals by the end of the trial and (D) – estimation of their volume. (E-H) 
Effects of clofazimine on growth of tumor xenografts obtained by orthotopic injections of BT-20 cells 
expressing firefly luciferase. (E) shows total luminescence of the tumor as the tumor size readout; (F) 
shows the parallel measurements of the tumor volume using electronic calipers. (G) demonstrates that 
the body weight of the animals was stable across the experiment. (H) shows tumor luminescence in 
control and clofazimine-treated animals on the 3rd week of treatment. 
 
Figure 4. Clofazimine elicits on-target anti-Wnt effects in TNBC xenograft tumors (A) 
Immunofluorescent stainings of β-catenin and MDR-1 reveal a dramatic effect of clofazimine on the 
Wnt signaling in tumor xenografts: MDR-1 levels are reduced, β-catenin switches from cytoplasmic to 
membrane localization. (B) Quantification of the effects of clofazimine on β-catenin localization: each 
cell from the section above was assigned to one of the four types depending on the observed pattern of 
β-catenin localization. Relative cell counts reveal that clofazimine treatment significantly enriches the 
proportion of cells with high membrane and low cytoplasmic β-catenin, while correspondingly 
decreasing the share of the cells positive for the cytoplasmic staining only. (C) Similar results were 
obtained using the scoring of the slides by the observed levels of cytoplasmic and membrane β-catenin. 
(D) Since MDR-1 staining is not homogenous but occurs in the form of "positive areas", we quantified 
the number of these areas per slide. This quantification demonstrates a significant decrease in the 
number of such areas in clofazimine-treated tumors. (E, F) Immunofluorescent stainings of the tumor 
sections for Ki67 and cleaved caspase-3 and their quantifications demonstrate a significant decrease in 
the proportion of proliferating cells in the clofazimine-treated tumor along with 5-fold elevated levels 
of apoptosis.  
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Figure 5. Clofazimine is compatible with cytotoxic chemotherapy producing additive effects (A) 
Treatment of the xenograft-bearing animals with clofazimine in combination with doxorubicin exerts a 
statistically significant decrease in tumor growth as compared to either doxorubicin or clofazimine as 
single agents. (B) Such combination did not affect the body weight of the animals. (C) Coefficient of 
drug interaction (CDI) was calculated for each day of the measurement and average of it is presented 
on the graph. The data demonstrate additivity of the clofazimine and doxorubicin effects in vivo. (D) 
Summary graph showing means of weighted average values of synergism and antagonism obtained 
from independent repeats of in vitro 2D drug interaction analysis on a panel of TNBC cell lines. 
Combenefit software analysis matrices and the representative experiments are shown in Supplementary 
Fig. 3 and 4. 
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Supplementary Figure 3. Drug interaction analysis
matrices of representative experiments on
corresponding TNBC cell l ines obtained by Combenefit
software. For most of the cell l ines the magnitude of the
observed effects is small and occurs in the narrow
concentration range. Summary of the data is shown on
Fig. 5D.
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Supplementary Figure 4. Representative surivival
curves of the drug combination study showing effects of
doxorubicin on clofazimine dose-response curves.
Summary of the data is shown on Figure 5D and
combination analysis on Supplementary Fig. 2.
  
Groups
Days
0 3 6 9 12 15 18 21
Urine
vehicle Normal (score 0)
doxorubicin Normal (score 0)
clofazimine Normal (score 0)
combination Normal (score 0)
Faeces
vehicle Normal (score 0)
doxorubicin Normal (score 0)
clofazimine Normal (score 0)
combination Normal (score 0)
Skin
vehicle Normal (score 0)
doxorubicin Normal (score 0)
clofazimine Normal (score 0)
combination Normal (score 0)
Orifices
vehicle Normal (score 0)
doxorubicin Normal (score 0)
clofazimine Normal (score 0)
combination Normal (score 0)
Posture
vehicle Normal (score 0)
doxorubicin Normal (score 0)
clofazimine Normal (score 0)
combination Normal (score 0)
Conscience
vehicle Normal (score 0)
doxorubicin Normal (score 0)
clofazimine Normal (score 0)
combination Normal (score 0)
Respiration
vehicle Normal (score 0)
doxorubicin Normal (score 0)
clofazimine Normal (score 0)
combination Normal (score 0)
Supplementary Table 1 . Scoring of the adverse reactions (see Supplementary Table 2) in mice during the
course of the combination study.
Score
Monitored factor 0 1 2 3
Urine Normal
Changes in color and 
appearance
Severe hematuria, 
severe incontinence, 
no urination for 
period of >24h
Faeces Normal Moist faeces
Diarrhea or 
excessive dryness
Severe or bloody 
diarrhea
General condition 
(skin, orifices, 
posture and 
conscience)
All factors normal
Decreased activity, 
slight abnormalities 
of posture or activity, 
aggression, fear
Severe loss of 
activity, poor 
grooming, skin 
dehydration
Near or complete 
paralysis,  cachexia 
or emaciation
Respiration Normal  
Rapid, shallow or 
abdominal breathing
Severely slowed or 
obstructed breathing
Supplementary Table 2. Scoring sheet used during the study:
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